Mesenchymal stromal cells (MSCs) used in cell therapies accumulate aging markers—increased inflammatory signaling, reactive oxygen species, epigenetic drift, and mitochondrial dysfunction—that reduce their therapeutic potency. Targeted rejuvenation strategies including epigenetic modulation, metabolic reprogramming, senolytic therapies, and telomere interventions restore stemness and functional capacity, directly improving the clinical efficacy of cell-based treatments.
Key Points
- MSC aging impairs stemness through IL-6/IL-8 secretion and ROS accumulation
- Epigenetic modulation and senolytics restore self-renewal and extend culture lifespan
- Rejuvenation addresses interconnected hallmarks: metabolism, senescence, telomeres, vesicles
Longevity Analysis
MSC rejuvenation addresses a fundamental constraint in regenerative medicine: the degradation of cellular repair capacity over time. The research identifies specific interference mechanisms—oxidative stress, epigenetic drift, mitochondrial dysfunction—that accumulate in cells intended for therapeutic use, then demonstrates that targeted interventions can reverse these changes and restore function. This has direct implications for any strategy relying on cellular regeneration: the quality of the cells themselves determines therapeutic outcome, and that quality can be systematically restored through metabolic support, senescent cell clearance, and epigenetic correction. The finding that multiple, complementary targets must be addressed simultaneously reflects how aging operates across interconnected cellular processes rather than through a single mechanism.
Original published by Wiley Aging Cell, by Astrid Sodomaco, Irene Bernardi, Aretha Rambaldi, Pierluigi Lombardi, Maura Rossi, Francesca Paris, Lucia Manzoli, Stefano Ratti, Francesco Alviano .